337 related articles for article (PubMed ID: 28443351)
1. Current and future chemical therapies for treating anaemia in chronic kidney disease.
Locatelli F; Del Vecchio L; Luise MC
Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
[TBL] [Abstract][Full Text] [Related]
2. Activin receptor ligand traps in chronic kidney disease.
Jelkmann W
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
[TBL] [Abstract][Full Text] [Related]
3. Investigational therapies for renal disease-induced anemia.
Schmid H; Jelkmann W
Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
[TBL] [Abstract][Full Text] [Related]
4. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
5. New Strategies for Anaemia Management in Chronic Kidney Disease.
Locatelli F; Del Vecchio L
Contrib Nephrol; 2017; 189():184-188. PubMed ID: 27951566
[TBL] [Abstract][Full Text] [Related]
6. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
7. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
[TBL] [Abstract][Full Text] [Related]
8. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
Locatelli F; Paoletti E; Del Vecchio L
Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
11. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
12. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
Del Vecchio L; Locatelli F
Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
[TBL] [Abstract][Full Text] [Related]
13. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
[TBL] [Abstract][Full Text] [Related]
14. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
Jelkmann W
Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis and treatment of anemia in chronic kidney disease].
Nangaku M
Rinsho Ketsueki; 2017; 58(10):1860-1863. PubMed ID: 28978825
[TBL] [Abstract][Full Text] [Related]
20. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
